Related Experiment Videos
Treatment of chlamydial pneumonia of infancy
Insights
Sulfisoxazole or erythromycin effectively treated chlamydial pneumonia in infants, stopping shedding and improving clinical status. Most infants recovered fully, suggesting these treatments are beneficial for this condition.
Area of Science:
- Pediatrics
- Infectious Diseases
- Microbiology
Background:
- Infants with untreated chlamydial pneumonia exhibit prolonged symptomatic periods and shed Chlamydia trachomatis.
- Chlamydial pneumonia is a significant concern in infancy, requiring effective therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy of sulfisoxazole and erythromycin ethyl succinate in treating chlamydial pneumonia of infancy.
- To assess the impact of these treatments on Chlamydia trachomatis shedding and clinical improvement in affected infants.
Main Methods:
- A study involving 32 infants diagnosed with chlamydial pneumonia.
- Treatment administered included sulfisoxazole (150 mg/kg/day) or erythromycin ethyl succinate (40 mg/kg/day) for approximately 14 days.
- Monitoring focused on nasopharyngeal shedding of C. trachomatis and clinical status changes.
Main Results:
- All infants ceased shedding C. trachomatis shortly after initiating treatment.
- Clinical improvement was observed in all infants, with 83% showing improvement within seven days of starting treatment.
- 27 of 28 infants examined demonstrated progression to complete recovery between two weeks and two months post-treatment.
Conclusions:
- Treatment with sulfisoxazole or erythromycin ethyl succinate appears beneficial for chlamydial pneumonia of infancy.
- The findings support the hypothesis that C. trachomatis plays a key role in this illness and that its eradication is clinically advantageous.
- These treatment regimens warrant consideration in the clinical management of infant chlamydial pneumonia, pending further controlled studies.
Abstract:
Infants with untreated chlamydial pneumonia shed Chlamydia trachomatis and are symptomatic for may weeks. We used sulfisoxazole, 150 mg/kg/day, or erythromycin ethyl succinate, 40 mg/kg/day, for approximately 14 days to treat 32 patients with chlamydial pneumonia of infancy, and observed them for nasopharyngeal shedding of C trachomatis and changing clinical status. All infants stopped shedding chlamydiae soon after treatment was started. After treatment, three of the 25 infants tested again became culture positive (but did not have clinical relapse). All infants improved clinically. In 24 (83%) of 29 infants, where the onset of improvement could be times, improvement began within seven days of starting treatment. Progression to complete recovery was observed in 27 of 28 infants examined between two weeks and two months of treatment completion. Neither the existence of concomitant viral infection nor the duration of illness or hospitalization before starting treatment influenced the interval between initiation of treatment and onset of clinical improvement. While these observations do not prove, they are at least compatible with the hypotheses that C trachomatis plays a central etiologic role in this illness and that termination of chlamydial infection is beneficial clinically. Pending the availibility of data from controlled studies, we believe that either of the treatment programs outlined warrant consideration in the clinical management of patients with chlamydial pneumonia of infancy.